Know what it is before deciding what it means.

AOD-9604 is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists AOD-9604 among bulk drug substances for use in compounding that may present significant safety risks. AOD-9604 is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

BPC-157 is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists BPC-157 among bulk drug substances for use in compounding that may present significant safety risks. BPC-157 is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 2 registered ClinicalTrials.gov studies cite BPC-157 (1 recruiting, 1 unknown); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Bremelanotide has FDA-approved prescription products (VYLEESI (AUTOINJECTOR) (NDA210557)). Bremelanotide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 10 registered ClinicalTrials.gov studies cite Bremelanotide (9 completed, 1 active not recruiting); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

CJC-1295 with DAC is listed in the CompoundedGuide registry with no verified FDA-approved product. CJC-1295 with DAC is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 1 registered ClinicalTrials.gov study cite CJC-1295 with DAC (1 terminated); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

CJC-1295 without DAC is listed in the CompoundedGuide registry with no verified FDA-approved product. CJC-1295 without DAC is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 1 registered ClinicalTrials.gov study cite CJC-1295 without DAC (1 terminated); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Elamipretide has FDA-approved prescription products (FORZINITY (NDA215244)). Elamipretide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 21 registered ClinicalTrials.gov studies cite Elamipretide (14 completed, 3 terminated, 2 recruiting, 1 active not recruiting, 1 available); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

GHK-Cu is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists GHK-Cu among bulk drug substances for use in compounding that may present significant safety risks. GHK-Cu is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 3 registered ClinicalTrials.gov studies cite GHK-Cu (1 completed, 1 not yet recruiting, 1 recruiting); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

GHK-Cu is listed in the CompoundedGuide registry with no verified FDA-approved product. GHK-Cu is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 3 registered ClinicalTrials.gov studies cite GHK-Cu (1 completed, 1 not yet recruiting, 1 recruiting); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Ipamorelin is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists Ipamorelin among bulk drug substances for use in compounding that may present significant safety risks. Ipamorelin is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 3 registered ClinicalTrials.gov studies cite Ipamorelin (2 completed, 1 active not recruiting); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

KPV is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists KPV among bulk drug substances for use in compounding that may present significant safety risks. KPV is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Liraglutide has FDA-approved prescription products (LIRAGLUTIDE (ANDA212552), LIRAGLUTIDE (ANDA212972), LIRAGLUTIDE (ANDA213155), LIRAGLUTIDE (ANDA214568), LIRAGLUTIDE (ANDA215245), LIRAGLUTIDE (ANDA215421), LIRAGLUTIDE (ANDA215503), LIRAGLUTIDE (ANDA217063), LIRAGLUTIDE (ANDA217234), LIRAGLUTIDE (ANDA217590), LIRAGLUTIDE (ANDA218115), SAXENDA (NDA206321), VICTOZA (NDA022341), XULTOPHY 100/3.6 (BLA208583)). FDA's drug shortage database lists 10 Liraglutide entries (Current, To Be Discontinued) as of 2026-07-25; that describes supply of an approved product, not whether compounding is lawful. Liraglutide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite Liraglutide (35 completed, 4 recruiting, 4 unknown, 3 not yet recruiting, 3 terminated, 1 active not recruiting); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

Mecasermin has FDA-approved prescription products (INCRELEX (BLA021839)). Mecasermin is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 40 registered ClinicalTrials.gov studies cite Mecasermin (25 completed, 8 terminated, 4 recruiting, 1 not yet recruiting, 1 unknown, 1 withdrawn); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

MOTS-c is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists MOTS-c among bulk drug substances for use in compounding that may present significant safety risks. MOTS-c is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 9 registered ClinicalTrials.gov studies cite MOTS-c (5 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting, 1 unknown); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

NAD+ is listed in the CompoundedGuide registry with no verified FDA-approved product. NAD+ is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite NAD+ (17 completed, 13 unknown, 11 recruiting, 4 terminated, 3 active not recruiting, 1 not yet recruiting, 1 withdrawn); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Oxytocin has FDA-approved prescription products (OXYTOCIN (ANDA091676), OXYTOCIN (ANDA200219), OXYTOCIN (NDA018243), OXYTOCIN (NDA018248), PITOCIN (NDA018261)). Oxytocin is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite Oxytocin (28 completed, 10 unknown, 4 recruiting, 4 withdrawn, 2 terminated, 1 enrolling by invitation, 1 not yet recruiting); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

Retatrutide is listed in the CompoundedGuide registry with no verified FDA-approved product. Retatrutide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 34 registered ClinicalTrials.gov studies cite Retatrutide (19 completed, 11 active not recruiting, 3 recruiting, 1 available); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Selank is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists Selank among bulk drug substances for use in compounding that may present significant safety risks. Selank is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 10 registered ClinicalTrials.gov studies cite Selank (8 completed, 2 unknown); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Semaglutide has FDA-approved prescription products (OZEMPIC (NDA209637), OZEMPIC / RYBELSUS (NDA213051), RYBELSUS (NDA213182), WEGOVY (NDA218316), WEGOVY / WEGOVY FLEXTOUCH / WEGOVY HD (NDA215256)). FDA's drug shortage database lists 3 Semaglutide entries (To Be Discontinued) as of 2026-07-25; that describes supply of an approved product, not whether compounding is lawful. Semaglutide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite Semaglutide (25 completed, 12 recruiting, 6 not yet recruiting, 3 active not recruiting, 2 enrolling by invitation, 2 unknown); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

Semax is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists Semax among bulk drug substances for use in compounding that may present significant safety risks. Semax is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Sermorelin is listed in the CompoundedGuide registry with no verified FDA-approved product. Sermorelin is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 42 registered ClinicalTrials.gov studies cite Sermorelin (28 completed, 6 terminated, 4 withdrawn, 3 recruiting, 1 unknown); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

TB-500 is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists TB-500 among bulk drug substances for use in compounding that may present significant safety risks. TB-500 is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 18 registered ClinicalTrials.gov studies cite TB-500 (11 completed, 2 recruiting, 2 terminated, 2 withdrawn, 1 not yet recruiting); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Tesamorelin has FDA-approved prescription products (EGRIFTA (BLA022505)). Tesamorelin is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 24 registered ClinicalTrials.gov studies cite Tesamorelin (14 completed, 4 terminated, 3 recruiting, 3 withdrawn); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

Thymosin alpha-1 is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists Thymosin alpha-1 among bulk drug substances for use in compounding that may present significant safety risks. Thymosin alpha-1 is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite Thymosin alpha-1 (18 completed, 11 recruiting, 10 unknown, 5 not yet recruiting, 3 active not recruiting, 2 withdrawn, 1 enrolling by invitation); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Thymosin beta-4 is listed in the CompoundedGuide registry with no verified FDA-approved product. FDA lists Thymosin beta-4 among bulk drug substances for use in compounding that may present significant safety risks. Thymosin beta-4 is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 18 registered ClinicalTrials.gov studies cite Thymosin beta-4 (11 completed, 2 recruiting, 2 terminated, 2 withdrawn, 1 not yet recruiting); registration is not evidence of approval, efficacy, or safety. Identity and regulatory status are pending source collection and editorial review. This is not medical advice.

Tirzepatide has FDA-approved prescription products (MOUNJARO / MOUNJARO (AUTOINJECTOR) / MOUNJARO KWIKPEN (NDA215866), ZEPBOUND / ZEPBOUND (AUTOINJECTOR) / ZEPBOUND KWIKPEN (NDA217806)). Tirzepatide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite Tirzepatide (20 completed, 12 recruiting, 10 not yet recruiting, 5 active not recruiting, 2 enrolling by invitation, 1 unknown); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.